Premium
Cefotaxime‐Ciprofloxacin Combination Therapy for Nontyphoid Salmonella Bacteremia and Paravertebral Abscess After Failure of Monotherapy
Author(s) -
Chang ChiaMing,
Lee HsinChun,
Lee NanYao,
Huang GuanCheng,
Lee IWen,
Ko WenChien
Publication year - 2006
Publication title -
pharmacotherapy: the journal of human pharmacology and drug therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.227
H-Index - 109
eISSN - 1875-9114
pISSN - 0277-0008
DOI - 10.1592/phco.26.11.1671
Subject(s) - cefotaxime , ciprofloxacin , medicine , bacteremia , combination therapy , salmonella , abscess , typhoid fever , osteomyelitis , surgery , antibiotics , microbiology and biotechnology , virology , bacteria , biology , genetics
Therapeutic failure of monotherapy with either a third‐generation cephalosporin or a fluoroquinolone against nontyphoid salmonellae has been observed in clinical practice. Combination therapy with both agents is recommended in the literature for treating life‐threatening infections. However, we know of no published case reports that indicate a therapeutic advantage of this combination therapy for nontyphoid salmonellae infections. We describe a 60‐year‐old man who had breakthrough bacteremia with vertebral osteomyelitis and paravertebral abscess caused by Salmonella enterica serotype Choleraesuis. This was not controlled with sequential monotherapy but was eventually cured with cefotaxime‐ciprofloxacin combination therapy. The Etest showed that the strain was susceptible to cefotaxime and ciprofloxacin, but resistant to nalidixic acid. Cefotaxime and ciprofloxacin in combination may be considered as an option for difficult‐to‐treat salmonellosis.